Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04325568 · ClinicalTrials.gov registry record · Phase 1
Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
A Phase 1 study, sponsored by New York University.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04325568 is a Phase 1 study that has completed, run by New York University. The registered enrollment target is 25 participants.
The verdict
NCT04325568, a Phase 1 study, has completed, sponsored by New York University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
While great strides are being made in identifying early signs that place people at a 'high risk state' for different illness conditions, at the same time, advances are being made in the identification of genes associated with 'high-risk states'. This study proposes to develop two innovative clinical tools that could greatly facilitate dissemination of a beneficial genetic malleability framing to high-risk youth in order to encourage increased treatment engagement and uptake of healthy behaviors. The impact of genetic information assumes special importance in the 'high-risk state' because achieving the best possible outcome is more likely if individuals actively choose to engage in beneficial treatment and health-promoting behaviors.
Interventions
- BEHAVIORAL PsyGist and Clinician Manual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2022-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04325568
The ClinicalTrials.gov registry entry for NCT04325568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York University, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PsyGist and Clinician Manual is the first listed.
NCT04325568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04325568 about?
NCT04325568 is a clinical study titled "Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis". While great strides are being made in identifying early signs that place people at a 'high risk state' for different illness conditions, at the same time, advances are being made in the identification of genes associated with 'high-risk states'. This study proposes to develop two innovative clinical...
What is the current status of trial NCT04325568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-11-16. Estimated completion is 2022-07-31.
What interventions are being tested in trial NCT04325568?
The interventions under investigation include: PsyGist and Clinician Manual (BEHAVIORAL).
Who is sponsoring clinical trial NCT04325568?
This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.